Compare Pfizer Inc (PFE) vs Ralph Lauren Corp (RL) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Pfizer Inc vs Ralph Lauren Corp — how do they compare? Pfizer Inc trades at $27.77 (market cap $158.56B), while Ralph Lauren Corp trades at $368.77 (market cap $21.89B). The key difference: Pfizer Inc is far larger — about 7.2× Ralph Lauren Corp's market cap, and Pfizer Inc pays the higher dividend (6.18%). Which is the better fit depends on your goals — on Pluang, investors hold Pfizer Inc for 158 Days and Ralph Lauren Corp for 84 Days on average.
| PFE | RL | |
|---|---|---|
Market Cap | $158.56B | $21.89B |
Volume | 44,138,282 | 481,617 |
Sector | Health | Consumer Cyclical |
52-Week High | $29.02 | $414.25 |
52-Week Low | $23.67 | $309.29 |
Typical Hold Time | 158 Days | 84 Days |
Enterprise Value | $210.06B | $22.95B |
Dividend Yield | 6.18% | 1.09% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Pfizer (PFE) trades at $27.82, up 1.22% with a bullish technical signal from moving averages. The company shows stable revenue around $62-63B with consistent earnings beats in recent quarters. Analysts maintain a $29.40 consensus target with 40% buy ratings. Recent news highlights Pfizer's focus on obesity and oncology pipelines as key growth drivers.
Pfizer offers value with defensive cash flows and dividend stability, though patent cliffs and margin compression present challenges. The stock's current valuation appears reasonable relative to sector peers, with upside potential if pipeline developments succeed. Key risks include competitive pressures and regulatory hurdles for new drug approvals.
Ralph Lauren (RL) trades at $361.14, down 2.04% on the day, with a bearish technical signal despite strong fundamental performance. The company has consistently beaten earnings expectations in recent quarters, with Q2 2026 EPS of $4.59 exceeding the $4.32 estimate. Revenue growth has accelerated from $6.2B in 2022 to $7.1B in 2025, while net income margins improved to 10.49%. Recent developments include global store expansion and sustainability initiatives under the Timeless by Design 2030 strategy.
RL presents a compelling investment case with strong profitability (37.54% ROE, 70.27% gross margins) and analyst consensus pointing to 26% upside to the $456.67 price target. However, the stock faces near-term technical headwinds and competitive pressures in the luxury apparel sector. The improving cash flow trajectory and dividend payments provide shareholder value support amid market volatility.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Pfizer Inc
Pfizer Inc. operates as a pharmaceutical company. The Company offers medicines, vaccines, medical devices, and consumer healthcare products for oncology, inflammation, cardiovascular, and other therapeutic areas. Pfizer serves customers worldwide.
Read more on PFE →About Ralph Lauren Corp
Founded by designer Ralph Lauren in 1967, Ralph Lauren Corp. designs, markets, and distributes lifestyle products in North America, Europe, and Asia. Its products include apparel, footwear, eyewear, jewelry, leather goods, home products, and fragrances. The company's brands include Ralph Lauren Collection, Polo Ralph Lauren, Lauren Ralph Lauren, and Double RL. Distribution channels for Ralph Lauren include wholesale (including department stores and specialty stores), retail (including company-owned retail stores and e-commerce), and licensing.
Read more on RL →
